Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature.
- Author:
Seiji MABUCHI
1
;
Kenichirou MORISHIGE
;
Takayuki ENOMOTO
;
Tadashi KIMURA
Author Information
- Publication Type:Original Article
- Keywords: Stage IVb; Cervical cancer; Carboplatin; Paclitaxel
- MeSH: Carboplatin; Gynecology; Humans; Obstetrics; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology 2010;21(2):93-96
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer. METHODS: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint. RESULTS: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%. CONCLUSION: TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.
